Eli Lilly (LLY) and Novo Nordisk (NVO) to dominate as TD Cowen lifts 2030 sales forecast for GLP-1 class of obesity/ diabetes ...

Tighter glucose control is known to reduce the risk of complications of diabetes like cardiovascular ... currently compatible with three of Lilly's insulin products, including Humalog and Lyumjev ...

Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of the ...

The strong performance of the diabetes product allowed Lilly to build its fourth quarter sales to $6.11 billion, with help from a supporting case of other products launched in the last few years ...

We expect diabetes and weight loss ... Ricks joined Lilly in 1996 as a business development associate. We sell different types of products and services to both investment professionals and ...

The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...

Feb. 6, 2025 /PRNewswire/ -- Today, the American Diabetes Association ® (ADA ... The resources are part of a nationwide collaboration between Lilly and the ADA to destigmatize obesity and ...

The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.